36389-07-8 Usage
Uses
Used in Organic Synthesis:
Ethyl benzofurazan-5-carboxylate is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions, contributing to the creation of a wide range of compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, ethyl benzofurazan-5-carboxylate is used as a versatile building block for synthesizing bioactive compounds, which can be further developed into potential drugs.
Used in Antimicrobial and Antiviral Applications:
Ethyl benzofurazan-5-carboxylate is used as a potential candidate for drug development due to its reported antimicrobial and antiviral properties, offering a promising avenue for combating infectious diseases.
Used in Specialty Chemicals Production:
ETHYL BENZOFURAZAN-5-CARBOXYLATE is utilized in the production of specialty chemicals, where its unique properties contribute to the development of high-value products.
Used in Biological Assays:
Ethyl benzofurazan-5-carboxylate is used as a fluorescent labeling reagent in biological assays, enabling researchers to track and study biological processes with enhanced visibility and precision.
Check Digit Verification of cas no
The CAS Registry Mumber 36389-07-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,3,8 and 9 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 36389-07:
(7*3)+(6*6)+(5*3)+(4*8)+(3*9)+(2*0)+(1*7)=138
138 % 10 = 8
So 36389-07-8 is a valid CAS Registry Number.
InChI:InChI=1/C9H8N2O3/c1-2-13-9(12)6-3-4-7-8(5-6)11-14-10-7/h3-5H,2H2,1H3
36389-07-8Relevant articles and documents
1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS
-
, (2010/01/30)
1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.
